TKIs exert their therapeutic effects by blocking multiple signaling pathways, including VEGFR, FGFR, PDGFR, and CSF1R, thereby not only directly inhibiting tumor cell proliferation but also modulating the TME to enhance the antitumor immune response of ICIs [160]. This evidence concerns the gene KDR and neoplasm.